Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors - Molecular dynamics study of the activated receptor-vasopressin-Gα systems

Journal of Peptide Science

Volumn 12, Issue 3, 2006, Pages 180-189

  Ślusarz, Magdalena J ^a   Giełdoń, Artur ^a   Ślusarz, Rafał ^a   Ciarkowski, Jerzy ^a  

^a UNIVERSITY OF GDA SK   (Poland)

Author keywords

AVP; GPCR activation; Molecular dynamics; Phospholipid bilayer; Vasopressin

Indexed keywords

2 OLEOYL 1 PALMITOYLPHOSPHATIDYLCHOLINE; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR; NEUROHYPOPHYSIS HORMONE; OXYTOCIN; OXYTOCIN RECEPTOR; RHODOPSIN; TRANSDUCIN; UNCLASSIFIED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; ENERGY TRANSFER; HORMONE BINDING; HYDRATION; LIPID BILAYER; MOLECULAR DYNAMICS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CATTLE; COMPUTER SIMULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; LIGANDS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; SEQUENCE ALIGNMENT; VASOPRESSINS;

MAMMALIA;

EID: 33644790823     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.714     Document Type: Article

References (82)

1. Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. J. Endocrinol. 1998; 156: 223-229.
2. Zingg HH. Vasopressin and oxytocin receptors. Baillieres Clin. Endocrinol. Metab. 1996; 10: 75-96.
3. Thibonnier M, Berti-Mattera LN, Dulin N, Conarty DM, Mattera R. Signal transduction pathways of the human VI-vascular, V2-renal, V3-pituitary vasopressin and oxytocin receptors. Prog. Brain Res. 1998; 119: 147-161.
4. Peter J, Burbach H, Arlan RA, Lolait SJ, Van Leeuwen FW, Mezey E, Palkovits M, Barberis C. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell. Mol. Neurobiol. 1995; 15: 573-595.
5. Wheatley M, Howl J, Morel A, Davies ARL. Homology between neurohypophysial hormone receptors. Biochem.J. 1993; 296: 519.
6. Hibert M, Hoflack J, Trumpp-Kallmeyer S, Mouillac B, Chim B, Mahe E, Cotte N, Jard S, Manning M, Barberis C. Functional architecture of vasopressin/oxytocin receptors. J. Recept. Signal Transduct. Res. 1999; 19: 589-596.
7. Postina R, Kojro E, Fahrenholz F. Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor. J. Biol. Chem. 1996; 271: 31593-31601.
8. Lebl M, Jošt K, Brtník F. Tables of analogs. In Handbook of Neurohypophysial Hormone Analogs, Vol. 1, Part 2, Jošt K, Lebl M, Brtník F (eds). CRC Press: Boca Raton, 1987: 127-267.
9. Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem. 1994; 269: 3304-3310.
10. Howl J, Wheatley M. Molecular pharmacology of V1a vasopressin receptors. Gen. Pharmacol. 1995; 26: 1143-1152.
11. Knepper MA, Valtin H, Sands JM. Renal actions of vasopressin. In Handbook of Physiology, Vol. III, Oxford University Press, USA: 2000; 496-529.
12. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, Brabet P, Rosenthal W. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357: 333-335.
13. Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J. Biol. Chem. 1994; 269: 27088-27092.
14. Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signalling pathways. Endocrinology 1997; 138: 4109-4122.
15. Kimura T, Tanizawa O, Mori K, Brownstein MJ, Okayama H. Structure and expression of a human oxytocin receptor. Nature 1992; 356: 526-529.
16. Fuchs AR, Fuchs F, Husslein P, Soloff MS, Fernstrom MJ. Oxytocin receptors and human parturition: a dual role for oxytocin in initiation of labor. Science 1982: 215: 1396-1398.
17. Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 2001; 81: 629-683.
18. Barberis C, Tribollet E. Vasopressin and oxytocin receptors in the central nervous system. Crit. Rev. Neurobiol. 1996; 10: 119-154.
19. Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res. 1998; 16: 10881-10890.
20. Ballesteros JA, Weinstein H. Integrated methods for modeling G-protein coupled receptors. Methods Neurosci. 1995; 25: 366-428.
21. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyamoto M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-745.
22. Lu Z-L, Saldanha JW, Hulme EC. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 2002; 23: 140-146.
23. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol. Pharmacol. 2001; 60: 1-19.
24. Sakmar TP. Structure of rhodopsin and the superfamily of seven-helical receptors: the same and not the same. Curr. Opin. Cell Biol. 2002; 14: 189-195.
25. Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 2003; 42: 2759-2767.
26. Dowell SJ, Brown AJ. Yeast assays for G-protein-coupled receptors. Receptors Channels 2002; 8: 343-352.
27. Meng EC, Bourne H. Receptor activation: what does the rhodopsin structure tell us?. Trends Pharmacol. Sci. 2001; 22: 587-593.
28. Hunyady L, Vauquelin G, Vanderheyden P. Agonist induction and conformational selection during activation of a G-protein-coupled receptor. Trends Pharmacol. Sci. 2003; 24: 81-86.
29. Bourne HR. How receptors talk to trimeric G proteins. Curr. Opin. Cell Biol. 1997; 9: 134-142.
30. Cabrera-Vera TM, Vanhauwe J, Thomas TO, Medkova M, Preininger A, Mazzoni MR, Hamm HE. Insights into G protein structure, function, and regulation. Endocr. Rev. 2003; 24: 765-781.
31. Sautel M, Milligan G. Molecular manipulation of G-protein-coupled receptors: a new avenue into drug discovery. Curr. Med. Chem. 2000; 7: 889-896.
32. Becker OM, Shacham S, Marantz Y, Noiman S. Modeling the 3D structure of GPCRs: advances and application to drug discovery. S. Curr. Opin. Drug. Discov. Devel. 2003; 6: 353-361.
33. Ballesteros J, Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Devel. 2001; 4: 561-574.
34. Laszlo FA, Laszlo F Jr, De Wied D. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 1991; 43: 73-108.
35. Ziai F, Walter R, Rosenthal IM. Treatment of central diabetes insipidus in adults and children with desmopressin. Arch. Intern. Med. 1978; 138: 1382-1385.
36. Russell SD, DeWald T. Vasopressin receptor antagonists: therapeutic potential in the management of acute and chronic heart failure. Am. J. Cardiovasc. Drugs 2003; 3: 13-20.
37. Mannucci PM. Treatment of von Willebrand's disease. N. Engl. J. Med. 2004; 351: 683-694.
38. Kill C, Wranze E, Wulf H. Successful treatment of severe anaphylactic shock with vasopressin. Int. Arch. Allergy Immunol. 2004; 134: 260-261.
39. Hubbell WL, Altenbach C, Hubbell CM, Khorana HG. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhrydryl reactivity, and disulfide cross-linking. Adv. Protein Chem. 2003; 63: 243-290.
40. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 1996; 274: 768-770.
41. Koenig BW. Structure and orientation of ligands bound to membrane proteins are reflected by residual dipolar couplings in solution NMR measurements. Chembiochem 2002; 3: 975-980.
42. Kisselev OG, Kao J, Ponder JW, Farm YC, Gautam N, Marshall GR. Light-activated rhodopsin induces structural binding motif in G protein alpha subunit. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 4270-4275.
43. Kisselev OG, Downs MA. Rhodopsin controls a conformational switch on the transducin gamma subunit. Structure 2003; 11: 367-373.
44. Hamm HE, Deretic D, Arendt A, Hargrave PA, König B, Hoffman KP. Site of G protein binding to rhodopsin mapped with synthetic peptides from the alpha subunit. Science 1988; 241: 832-835.
45. Martin EL, Rens-Domiano S, Schatz PJ, Hamm HE. Potent peptide analogues of a G protein receptor-binding region obtained with a combinatorial library. J. Biol. Chem. 1996; 271: 361-366.
46. Aris L, Gilchrist A, Rens-Domiano S, Meyer C, Schatz PJ, Dratz EA, Hamm HE. Structural requirements for the stabilization of metarhodopsin II by the C terminus of the alpha subunit of transducin. J. Biol. Chem. 2001; 276: 2333-2339.
47. Janz JM, Farrens DL. Rhodopsin activation exposes a key hydrophobic binding site for the transducin alpha-subunit C terminus. J. Biol. Chem. 2004; 279: 29767-29773.
48. Koenig BW, Kontaxis G, Mitchell DC, Louis JM, Litman BJ, Bax A. Structure and orientation of a G protein fragment in the receptor bound state from residual dipolar couplings. J. Mol. Biol. 2002; 322: 441-461.
49. Ślusarz R, Ciarkowski J. Interaction of class A G protein-coupled receptors with G proteins. Acta Biochim Pol. 2004; 51: 129-136.
50. Ślusarz Md, Ślusarz R, Ciarkowski J. Molecular dynamics simulation of human neurohypophyseal receptors complexed with oxytocin - modeling of an activated state. J. Pept. Sci. in press, DOI: 10.1002/psc7l3.
51. Case DA, Pearlman DA, Caldwell JW, Cheatham TE, Wang J, Ross WS, Simmerling CL, Darden TA, Merz KM, Stanton RV, Cheng A, Vincent JJ, Crowley M, Tsui V, Gohlke H, Radmer R, Duan Y, Pitera J, Massova I, Seibel GL, Singh UC, Weiner P, Kolhnan PA. Amber 7. University of California: San Francisco, 2002.
52. Cieplak P, Cornell WD, Bayly C, Kollman PA. Application of the multimolecule and multiconformation RESP methodology to biopolymers: charge derivation for DNA, RNA, and proteins. J. Comput. Chern. 1995; 16: 1357-1377.
53. Bayly CI, Cieplak P, Cornell WD, Kollman PA. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993; 97: 10269-10280.
54. Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JH, Koseki S, Matsunaga N, Nguyen KA, Su S, Windus TL, Dupuis M, Montgomery JA. The general atomic and molecular electronic structure system. J. Comput. Chem. 1993; 14: 1347-1363.
55. Langs DA, Smith GD, Stezowski JJ, Hughes RE. Structure of pressinoic acid: the cyclic moiety of vasopressin. Science 1986; 232: 1240-1242.
56. Sybyll 6.8. Tripos Inc: St. Louis.
57. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem. 1998; 19: 1639-1662.
58. Solis FJ, Wets JB. Minimization by random search techniques. Math. Oper. Res. 1981; 6: 19-30.
59. Goodsell DS, Morris GM, Olson AJ. Docking of flexible ligands: applications of AutoDock. J. Mol. Recognit. 1996; 9: 1-5.
60. Ślusarz MJ, Ślusarz R, Kaźmierkiewicz R, Trojnar J, Wioniewski K, Ciarkowski J. Molecular modeling of the neurohypophyseal receptor/atosiban complexes. Protein Pept. Lett. 2003; 10: 295-302.
61. Ślusarz R, Ślusarz Md, Kaźmierkiewicz R, Lammek B. Molecular modeling of interaction of the vasopressin analogs with vasopressin and oxytocin receptors. QSAR Comb. Sci. 2003; 22: 865-872.
62. Kirkpatrick S, Gelatt CD Jr, Vecchi MP. Optimization by simulated annealing. Science 1983; 220: 671-680.
63. Clore GM, Nilges M, Brünger AT, Karplus M, Gronenborn AM. A comparison of the restrained molecular dynamics and distance geometry methods for determining three-dimensional structures of proteins on the basis of interproton distance restraints. FEBS Lett. 1987; 213: 269-277.
64. Murzyn K, Róg T, Jezierski G, Takaoka Y, Pasenkiewicz-Gierula M. Effects of phospholipid unsaturation on the membrane/water interface: a molecular simulation study. Biophys. J. 2001; 81: 170-183.
65. Pasenkiewicz-Gierula M, Murzyn K, Róg T, Czaplewski C. Molecular dynamics simulation studies of lipid bilayer systems. Acta Biochim. Pol. 2000; 47: 601-611.
66. Ewald PP. Die Berechnung optischer und elektrostatischer Gitterpotentiale. Ann. Phys. 1921; 64: 253-287.
67. Darden T, York D, Petersen L. Partial mesh Ewald: an N × log(N) method for Ewalds sums in large systems. J. Chem. Phys. 1993; 98: 10089-10092.
68. Essmarm UL, Perera ML, Berkowitz T, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J. Chem. Phys. 1995: 103: 8577-8593.
69. Jorgensen WL, Tirado-Rives J. The OPLS potential functions for proteins. Energy minimization for crystals of cyclic peptides and crambin. J. Am. Chem. Soc. 1988; 110: 1657-1666.
70. Walter R. Identification of sites in oxytocin involved in uterine receptor recognition and activation. Fed. Proc. Am. Soc. Exp. Biol. 1977; 36: 1872-1878.
71. Wood SP, Tickle IJ, Treharne AM, Pitts JE, Mascarenhas Y, Li JY, Husain J, Cooper S, Blundell TL, Hruby VJ, Wyssbrod HR, Buku A, Fishman AJ. Crystal structure analysis of deaminooxytocin: conformational flexibility and receptor binding. Science 1986; 232: 633-636.
72. Manning M, Bankowski K, Sawyer WH. Selective agonists and antagonists of vasopressin. In Vasopressin, Gash DW, Boer GJ (eds). Plenum Publishing: New York, 1987; 335-368.
73. Sawyer WH, Grzonka Z, Manning M. Neurohypophyseal peptides. Design of tissue-specific agonists and antagonists. Mol. Cell. Endocrinol. 1981; 22: 117-134.
74. Mouillac B. Chini B, Balestre MN, Elands J, Trumpp KS, Hoflack J, Hibert M, Jard S, Barberis C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J. Biol. Chem. 1995: 270: 25771-25777.
75. Manning M, Sawyer WH. The development of selective agonists and antagonists of vasopressin. In Vasopressin, Schrier RW (ed.). Raven Press: New York, 1985: 131-144.
76. Sawyer WH, Acosta M, Balaspiri L, Judd J, Manning M. Structural changes in the arginine vasopressin molecule that enhance antidiuretic activity and specificity. Endocrinology 1974; 94: 1106-1115.
77. Gillessen D, du Vigneaud V. The synthesis and pharmacological properties of 4-decarboxamide-8-lysinevasopressin, 5-decarboxamide-8-lysinevasopressin, and their 1-deamio, analogs. J. Biol. Chem. 1967; 242: 4806-4812.
78. Cotte N, Balestre MN, Aumelas A, Mahé E, Phalipou S, Morin D, Hibert M, Manning M, Durroux T, Barberis C, Mouillac B. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. Eur. J. Biochem. 2000; 267: 4253-4263.
79. Chan WY, Wo NC, Cheng LL, Manning M. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor. J. Pharmacol. Exp. Ther. 1996; 277: 999-1003.
80. Ślusarz MJ, Ślusarz R, Meadows R, Trojnar J, Ciarkowski J. Molecular dynamics of complexes of atosiban with neurohypophyseal receptors in the fully hydrated phospolipid bilayer. QSAR Comb. Sci. 2004; 23: 536-545.
81. Ślusarz MJ, Giełdoń A, Ślusarz R, Meadows R, Trojnar J, Ciarkowski J. Study of new oxytocin antagonist barusiban (Fe200 440) affinity toward human oxytocin receptor versus vasopressin V1a and V2 receptors - molecular dynamics simulation in POPC bilayer. QSAR Comb. Sci. 2005; 24: 603-610.
82. Colson AO, Perlman JH, Jinsi-Parimoo A, Nussenzveig DR, Osman R, Gershengom MC. A hydrophobic cluster between transmembrane helices 5 ∼and 6 ∼Constrains the thyrotropin-releasing hormone receptor in an inactive conformation. Mol. Pharmacol. 1998; 54: 968-978.